Sugemalimab, a fully human, full-length, IgG4 monoclonal antibody (mAb) targeting programmed death ligand 1 (PD-L1), exhibits anticancer activities and is applicable in non-small cell lung cancer research [1].
CAS Number:
[2256084-03-2]
* VAT and and shipping costs not included. Errors and price changes excepted